Severity Index of Neonatal Septicemia Using Score for Neonatal Acute Physiology (SNAP) II
NCT ID: NCT03746743
Last Updated: 2018-11-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2017-09-01
2018-09-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Accuracy of Scoring Systems for Risk Assessment in Neonatal Intensive Care Unit
NCT05763316
THE VALUE OF INTERLEUKIN 6 AS A DIAGNOSTIC MARKER IN NEONATAL SEPSIS
NCT05585957
An Audit Study on Management of Neonates With Neonatal Sepsis Admitted to Asyut University Children Hospital
NCT03634891
Neonatal Sepsis Workup for High Risk Newborns - Evaluation of Need and Ways to Prevent
NCT02061150
Serum Presepsin as Early Predictor for Neonatal Early-onset Sepsis
NCT05022043
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Population of study \& disease condition:
Neonates with septicemia admitted to NICUs in CHILDREN'S HOSPITAL, CAIRO UNIVERSITY and in ELGALAA Children's MILITARY HOSPITAL.
Inclusion criteria:
1. Type of patient: Neonates with septicemia.
2. Age of patient: From 0-28 Days.
3. Sex: males and females.
Exclusion criteria:
1. Neonates with proved inborn error of metabolism.
2. Neonates with multiple congenital anomalies.
3. Neonates with severe birth asphyxia (APGAR score \<4 at 5 minutes).
Methodology in details:
We will have 2 groups, each of them 50 neonates with septicemia. One group of premature neonates (32-36 weeks), the other group of full term neonates (\>37 weeks).
All included Patients will be subjected to the following:
1. Full history with emphasis of relevant data as follows:
Date of birth, gestational age (AGA or SGA), gender, day of sepsis onset.
2. Clinical assessment:
Full systems examination.
3. Diagnosis of sepsis:
* By abnormal Total leucocytic count or I/T ratio or CRP with clinical Suggestion (poor feeding, hepatomegaly, apnea, tachypnea, lethargy, …).
* Confirm diagnosis by blood culture.
Sepsis will be considered severe if the neonate has sepsis plus one of the following: 1) cardiovascular organ dysfunction (hypotension or need for vasoactive drug) 2) 2 of the following (metabolic acidosis, increase lactic acid, oliguria, Prolonged capillary refill time) 3) Organ dysfunction (respiratory, renal, neurologic, hematologic).
4. SNAP II score:
For all neonates included in the study and its data collection within 24 hours from onset of sepsis, in the form of:
* Lowest mean blood pressure.
* Worst ratio of pao2/fio2
* Lowest temperature.
* Lowest serum PH.
* Occurrence of multiple seizures.
* Urine output\<1 ml/kg/hour.
5. Follow up:
Follow up all neonates included in the study for 14 days: for morbidity and mortality.
6. Diagnosis of organ dysfunction:
Respiratory: by CXR and clinical examination. CVS: by blood pressure, capillary refill time, shock and need for inotropes. Renal: by urine output, kidney function tests. Hematology: by picture of DIC or pancytopenia. Neurology: by seizures, dilated fixed pupil.
Possible Risk:
None.
Primary outcomes:
Using Score for Neonatal Acute Physiology II as a Predictor of Mortality and Organ Dysfunction in Neonates with Septicemia.
Secondary outcomes:
Early anticipation of clinical manifestations of sepsis which will correlate most with poor outcome.
Sample size:
100 Neonates with septicemia admitted to NICUs in CHILDREN'S HOSPITAL, CAIRO UNIVERSITY and in ELGALAA Children's MILITARY HOSPITAL.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Preterm neonates
Neonates born between 32 and 37 weeks gestation
score for neonatal sepsis
score for neonatal sepsis to predict morbidity
Fullterm neonates
Neonates born at or after 37 weeks gestation
score for neonatal sepsis
score for neonatal sepsis to predict morbidity
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
score for neonatal sepsis
score for neonatal sepsis to predict morbidity
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age of patient: From 0-28 Days.
3. Sex: males and females.
Exclusion Criteria
2. Neonates with multiple congenital anomalies.
3. Neonates with severe birth asphyxia (APGAR score \<4 at 5 minutes).
1 Day
28 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ahmed Mahmoud Ali Ali Youssef
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Mahmoud Ali Ali Youssef
Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nermin R Mohamed, MD
Role: PRINCIPAL_INVESTIGATOR
Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty Of medicine Cairo University
Giza, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SNAP II Score
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.